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Abstract
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, recently developed as a drug of choice for initial anti-retroviral 
(ARV) treatment of HIV-1 infection, whereas estradiol is a major component of hormonal contraceptives. Both drugs have 
effects on lipid metabolism, impairment of adipocyte differentiation and alteration of adipose tissue distribution and function.
This study investigated the effects of different concentrations of either rilpivirine or estradiol either alone or in combination 
on adipocyte differentiation and adipocytokines status in vitro in the absence and presence of β-naphthoflavone, (BNF),a 
potent agonist of the aryl hydrocarbon receptor. 3T3-L1 human pre-adipocytes were cultured and differentiated with different 
concentrations of treatment drugs. After 10 days of differentiation procedure, cells were examined for their morphology and 
viability. Glycerol,adiponectin, leptin, resistin and interleukin-8 (IL-8) were quantified using commercially available kits. 
The results show that either rilpivirine or estradiol individually or during their combination can evoke significant increases 
in glycerol release and a concomitant significant decrease of adiponectin from adipocytes. These effects were dose–depend-
ent. The effects of combined treatments were much larger than individual concentration for each drug. Both drugs had little 
of no effect on leptin levels, except for a small decrease with 10 µM rilpivirine alone or when combined with estradiol. 
In addition, both drugs evoked small increases in the release of resistin and interleukin-8 with significant values at higher 
doses compared to untreated adipocytes.When adipocytes were pretreated with BNF, either rilpivirine or, estradiol or when 
combined evoked a much larger release in glycerol and a much larger decrease in adiponectin compared to the absence of 
BNF. In contrast, BNF pretreatment had little of no effect on either leptin, resistin or IL-8 metabolism compared to the 
results obtained in the presence of either rilpivirine or estradiol alone or in combination.These results show that rilpivirine 
and estradiol either alone or when combined or pretreated with BNF can evoke marked effects on glycerol and cytokines 
levels from adipocytes. However, their mechanism (s) in inducing adipogenesis warrants further investigation of different 
transcription factors at gene expression levels.
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Introduction
Obesity is a major global health problem and if left 
untreated, it may lead to major complications [1]. It is 
attributed to a number of factors including over-eating, 
sedentary lifestyle, lack of physical activity, genetics, 
diets rich in carbohydrate, frequency of eating, hormonal 
and various psychological factors as well as others. Some 
medications are also associated with weight gain. These 
include certain anti-depressants, anti-convulsants, some 
diabetes medication and certain hormones including lep-
tin, insulin, estrogens, androgens and growth hormones 
[2, 3].
Rilpivirine is a prescription medicine for the treatment 
of HIV infection in adults and children. Although the 
approval document of rilpivirine issued in 2011 by the 
U.S. Food and Drug Administration (FDA) included fat 
re-distribution among its warnings and precautions, con-
tradictory results showing its effect on the adipose tissue 
distribution and function have been presented by previ-
ously conducted clinical trials [4–7]. On the other hand, 
17β-estradiol is a major component of hormonal contra-
ceptives and it acts primarily as an agonist of the estrogen 
receptor (ER). Several studies have provided evidence of a 
hormonal regulation of pre-adipocyte proliferation [8, 9]. 
Estrogen promotes subcutaneous fat and regulate adipose 
tissue distribution through its receptors, ERα and ERβ 
[10, 11]. 17β-estradiol has been shown to have stimula-
tory effects on proliferation of female rat pre-adipocytes 
[12] and in human pre-adipocytes [13].
The British HIV guideline for the management of HIV 
infection indicated that rilpivirine is an appealing option 
to consider in women of childbearing potential. At the 
same time, it also warns of the significant pharmacoki-
netic and pharmaco-dynamic interactions that have been 
reported between the anti-retroviral (ARV) drugs and 
hormonal agents. Inducers of hepatic enzymes by ARVs 
may result in increased breakdown of estrogen that can 
compromise contraceptive efficacy [14]. In addition, both 
of these drugs are known to alter lipid metabolism and fat 
distribution in the body [15, 16]. Therefore, a mechanis-
tic insight into the elucidative role of concomitant use of 
rilpivirine and estradiol would provide more robust and 
reliable prediction of their potential interactions on the 
adipogenesis pathway.
Organic pollutants such as β-naphthoflavone (BNF) 
tend to escape from the body metabolic system and accu-
mulate in the white adipose tissue (WAT),thereby affect-
ing its physiological role, leading to the development of 
obesity-related disorders [17]. The mechanisms through 
which such chemicals modulate the differentiation, metab-
olism, and secretory function of adipocytes are numerous 
[18–21]. Aryl hydrocarbon receptor (AhR), a cytosolic 
ligand-activated transcription factor that participates in 
a variety of metabolic processes, including detoxifica-
tion and adipogenesis, has been reported to be function-
ally present in rodent adipose tissue [17, 22]. Activated 
AhR modulates expressions of various genes involved in 
xenobiotic-metabolizing pathways, such as cytochrome 
P4501A1 (CYP1A1) [23–25]. CYP1A induction may be 
used as a biomarker of exposure to toxic substances in 
order to ascertain whether in vitro models could be useful 
in investigating the bio activation potential of environ-
mental contaminants. Therefore, this study investigated the 
effect of rilpivirine and estradiol either alone or in com-
bination on the adipose cells measuring free glycerol and 
a number of inflammatory markers including leptin, and 
adiponectin, resistin and IL-8 which are associated with 
adipocyte function. In another series of experiments, rilpi-
virine and estradiol were combined with an environmental 
pollutant, BNF to determine any inhibitory or stimulating 
effects.
Materials and methods
Material
Adipose derived mesenchymal stem cells were obtained 
from  HimediaTMCat.# CCK011. Complete medium and 
adipogeneic differentiation medium were also purchased 
from Himedia Cat.# AL521 and Cat.# AL537 respectively. 
Cytotoxicity kit was purchased from  PromegaTMCat.# 
G1780 to check the cell viability. Free glycerol and Adi-
ponectin were measured using Abcam’s Lipolysis Assay 
kit (Cat. #ab185433) and Human Adiponectin ELISA kit 
(Cat.#ab99968). Other adipocytokines were quantified 
using the kits from Sigma Aldrich: Human Leptin Elisa 
kit (RAB0333), Human Interleukin-8(IL-8) kit (Cat. # 
RAB0319) and Human resistin ELISA kit (Cat. # RAb0419).
Cell proliferation, seeding and differentiation
3T3-L1 adipose cells were incubated for 3–4 h in a humidi-
fied  CO2 incubator with 5%  CO2 at 37 °C temperature and 
then replenished with complete medium. Cells were sub-
cultured after reaching 70–80% confluency by gently aspi-
rating the spent medium and washing the cells with 2–3 ml 
of Dulbecco’s phosphate buffer saline (DPBS). Fresh flasks 
were seeded at a density of approx. 0.125 × 106 cells/cm2 
of the flask. This seeding density was recommended as per 
the manufacturer’s instructions (Himedia Cat.# CL007). Dif-
ferentiation into adipose cells was done in the presence of 
the same culture medium as used before and supplemented 
with adipogenic differentiation medium.
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Addition of treatment drugs was initiated on day 0 and 
continued throughout the differentiation period of 10 days. 
Fresh drugs were added each time the medium was replaced. 
The medium was replaced every 2–3 days. Stock solutions 
of 17-β estradiol and BNF were prepared in differentiation 
medium while DMSO was used for preparing rilpivirine. 
They were then aliquoted and stored at − 20 °C prior to use. 
Working solutions of the treatment drugs were prepared by 
diluting them further.
Lactate dehydrogenase assay for the measurement 
of cell viability
Potential cytotoxic effects of drugs were determined using 
a CytoTox 96 non-radioactive cytotoxicity kit following the 
manufacturer’s protocol. Cell viability was assessed on day 0, 
5 and 10.CytoTox 96® reagent was added to each well contain-
ing the sample and incubated for 30 min. Stop Solution was 
added, and the absorbance signal was measured at 490 nm.
Quantification of free glycerol
Commercially available Abcam’s Lipolysis Assay kit was 
used to measure glycerol released from 3T3-L1 cells. A 
volume of 0, 2, 4, 6, 8 and 10 µL of 1 mM glycerol stand-
ard was added into series of wells to generate 0, 2 ,4 ,6, 8 
and 10 nmol/well of glycerol standards and the volume of 
each well was adjusted to 50 µL with Glycerol assay buffer 
followed by 50 µL of the reaction mixture. Incubation was 
done for 30 min and absorbance was read at 570 nm. Sample 
readings were applied to the standard curve to get nmol of 
glycerol amount in the sample wells.
Quantification of inflammatory adipocytokines
The concentrations of adipokines and cytokines released by 
adipocytes following treatment with the drugs and accumu-
lated in the cell culture medium were measured at the end 
of 10 days of differentiation process employing established 
specific assay kits.
Commercially available Human Leptin Elisa kit was 
used for the quantitative measurement of leptin in cell cul-
ture supernatant. Standards were prepared by subsequent 
serial dilution of leptin standard using 1X Assay diluent 
B. A volume of 100 µL of each standard and sample was 
added into appropriate wells and incubated overnight at 
4 °C. The plate was washed four times with 300 µL of 
Wash Buffer. After this, 100 µL of 1X Detection Antibody 
was added and incubated for 1 h followed by washing step. 
A volume of 100 µL of HRP-Streptavidin was added to 
each well and incubated for 45 min. The plate was washed 
again and 100 µL of TMB reagent was added to each well. 
It was then incubated for 30 min. Reaction was stopped by 
adding 50 µL of Stop solution and absorbance was taken 
at 450 nm. Sample concentrations were calculated using 
the equation of the standard curve.
Abcam’s Human Adiponectin ELISA kit was used for 
the quantitative measurement of human adiponectin in cell 
culture supernatant following the manufacturer’s instruc-
tions. Serially diluted standards were prepared using 
adiponectin stock standard. A volume of 100 µL of each 
standard and sample was added into appropriate wells and 
incubated overnight at 4 °C. Wells were washed four times 
with 300 µL of 1X wash solution. After this, a volume of 
100 µL of 1X biotinylated detection antibody was added 
to each well and incubated for 1 h. Wells were washed as 
before and 100 µL of 1X HRP-streptavidin solution was 
added to each well and incubated for 45 min. A volume 
of 100 µL TMB substrate reagent was added followed by 
30 min of incubation. Reaction was stopped by 50 µL of 
stop solution and absorbance was read at 450 nm.
Human interleukin-8 (IL-8) kit was used for the quanti-
tative measurement of IL-8 from cell culture supernatant 
following the manufacturer’s protocol. Serial dilution was 
performed to prepare standards. Assay Diluent B served 
as the zero standard (0 pg/mL). A volume of 100 µL of 
either standard or sample was added into appropriate wells 
and incubated for 2.5 h. The wells were washed four times 
with 300 µL of 1X wash solution. After this, 100 µL of 
1X prepared biotinylated detection antibody and incubated 
for 1 h. A volume of 100 µL of prepared HRP-streptavidin 
solution was then added and incubated for 45 min followed 
by 100 µL of TMB reagent and 30 min incubation. Finally, 
a volume of 50 µL of stop solution was added and absorb-
ance was read at 450 nm. Sample concentrations were cal-
culated using the equation from the standard curve.
Resistin was quantified from the cell culture supernatant 
using the human resistin ELISA kit following the protocol 
from the manufacturer. Serially diluted standards were pre-
pared using resistin stock standard. A volume of 100 µL of 
standard or sample was added into appropriate wells and incu-
bated for 2.5 h. Wells were washed four times with 300 µL of 
1X wash solution followed by 100 µL of 1X prepared bioti-
nylated detection Antibody and 1-h incubation. After this, a 
volume of 100 µL of HRP-streptavidin was added to each well 
and incubated for 45 min. After washing, a volume of 100 µL 
of TMB Reagent was added and incubated for 30 min. Finally, 
a volume of 50 µL of stop solution was added and absorbance 
was read at 450 nm .Sample concentrations were calculated 
using the equation from the standard curve.
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Statistical analysis
All control and test data were analyzed using the Mega Stat 
software from Microsoft Excel. Chi Square goodness of 
fit test was applied and the p value was obtained. All data 
obtained were expressed as mean ± standard deviation (S.D). 
Each experiment was repeated three times but performed in 
duplicate (n = 6) to ensure the accuracy of results. A value 
of p < 0.05 was taken as significant.
Results
Morphological examination
Figure 1 shows human pre-adipocytes that were differenti-
ated in culture in the presence of different concentrations of 
either rilpivirine or estradiol either alone or combined for 
a period of 10 days. The results show that untreated cells 
on day 0 display spindle shaped, fibroblast-like appearance 
with undetectable lipids. However, with the progression of 
adipogenesis, mature adipocytes attain a round shape and 
become laden with lipids.
Fig. 1  Confocal image photographs (a–f) taken at ×10 magnification of human adipocytes showing the effects of rilpivirine, estradiol and their 
combination on the morphology of the cells. Each image is typical of six such different experiments
Table 1  Cell viability 
measurement of human 
pre-adipocytes treated with 
rilpivirine and estradiol either 
alone or during combination
Pre-adipocytes were treated with the different concentrations of drugs for 10 days. Data are expressed as % 
viability ± SD relative to the control, > 0.05 for treatment compared to control; n = 6
Drugs Dosage (µM) % Viability ± SD
Day 0 Day 5 Day 10
Control 0 97.23 ± 0.003 97.14 ± 0.002 96.47 ± 0.006
Rilpivirine 1 97.27 ± 0.006 96.92 ± 0.003 96.71 ± 0.006
Rilpivirine 5 96.89 ± 0.013 95.65 ± 0.05 95.17 ± 0.01
Rilpivirine 10 97.23 ± 0.006 96.25 ± 0.01 95.82 ± 0.01
Estradiol 0.01 97.27 ± 0.006 96.05 ± 0.02 95.68 ± 0.01
Estradiol 0.05 97.13 ± 0.002 96.56 ± 0.03 95.86 ± 0.01
Estradiol 0.1 97.23 ± 0.003 95.04 ± 0.003 95.68 ± 0.008
Rilpivirine + Estradiol 1 + 0.01 97.23 ± 0.005 95.69 ± 0.04 95.47 ± 0.001
Rilpivirine + Estradiol 5 + 0.05 97.58 ± 0.013 96.84 ± 0.004 94.71 ± 0.01
Rilpivirine + Estradiol 10 + 0.1 97.23 ± 0.003 95.89 ± 0.04 94.75 ± 0.01
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Cell viability assessment
Cell viability was assessed for the two series of three differ-
ent experiments measured in duplicates (n = 6) by employ-
ing lactate dehydrogenase assay. The results are shown in 
Tables 1 and 2. Values were expressed as the percentage 
test cells surviving compared to control cells. The results in 
these tables show no significant (p > 0.05) difference in cell 
viability with drug treatments compared untreated control.
Measurements of levels of free glycerol 
and adipocytokines in untreated and treated 
adipocytes after 10 days
In this and subsequent figures, values are presented as 
means ± SD from duplicate set of experiments expressed 
relative to values from untreated control cells. n = 6;* 
p < 0.05 for control compared to drug treatments.
The data presented in Fig. 2 show the effects of different 
concentrations of either rilpivirine or estradiol alone or in 
combination on the release of free glycerol from human 
adipocytes. The results show that all drug treatments can 
evoke significant (p < 0.05) increases in free glycerol 
release from human adipocytes compared to untreated 
control, except for 0.01 µM estradiol, which induces only 
a small increase in free glycerol.
Figure 3 shows the effect of rilpivirine and estradiol 
either alone or in combination on the release of leptin 
by human adipocytes in culture for 10 days. The results 
show the different types of drug treatments had little or 
no effect on leptin release, except for 10 µM rilpivirine 
alone or when it was combined with 0.1 µM estradiol 
Table 2  Cell viability of human 
pre-adipocytes treated with 
rilpivirine and estradiol either 
alone or in combination but 
in the continuous presence of 
200 µM BNF: Pre-adipocytes 
were treated with the different 
concentrations of drugs for 10 
days
Data are expressed as % viability ± SD relative to the control; p > 0.05 for control compared to treatments; 
n = 6
Drugs Dosage (µM) % Viability ± SD
Day 0 Day 5 Day 10
Control 0 97.23 ± 0.004 96.61 ± 0.075 96.64 ± 0.03
Rilpivirine + BNF 1 + 200 97.06 ± 0.005 96.86 ± 0.04 96.22 ± 0.004
Rilpivirine + BNF 5 + 200 97.23 ± 0.003 96.84 ± 0.01 96.82 ± 0.01
Rilpivirine + BNF 10 + 200 97.23 ± 0.003 96.72 ± 0.007 96.22 ± 0.001
Estradiol + BNF 0.01 + 200 97.16 ± 0.009 96.74 ± 0.01 96.47 ± 0.004
Estradiol + BNF 0.05 + 200 97.09 ± 0.004 95.26 ± 0.04 96.54 ± 0.01
Estradiol + BNF 0.1 + 200 97.23 ± 0.006 95.26 ± 0.05 96.82 ± 0.01
Rilpivirine + Estradiol + BNF 1 + 0.01 + 200 97.09 ± 0.003 94.66 ± 0.01 96.43 ± 0.007
Rilpivirine + Estradiol + BNF 5 + 0.05 + 200 96.96 ± 0.002 94.78 ± 0.05 96.78 ± 0.02
Rilpivirine + Estradiol + BNF 10 + 0.1 + 200 97.09 ± 0.004 96.44 ± 0.01 96.43 ± 0.01
Fig. 2  Bar charts showing the 
effects of different concentra-
tions of either rilpivirine or 
estradiol alone or in combi-
nation on the release of free 
glycerol from human adipocytes 
following 10 days in culture
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when a significant (p < 0.05) decrease in leptin release 
were observed.
The results presented in Fig. 4 show the effect of rilpi-
virine and estradiol either alone or in combination on the 
release of adiponectin from human adipocytes in cul-
ture for 10 days. The results show significant (p < 0.05) 
decreases in adiponectin release for all drug treatments 
compared to untreated control, except for 1 µM rilpivirine.
The results show effect of rilpivirine and estradiol either 
alone or in combination on the release of resistin from 
human adipocytes in culture for 10 days. The data reveal 
significant (p < 0.05) release in resistin for all drug treat-
ments compared to untreated control except for 1 and 5 µM 
rilpivirine and rilpivirine (1 and 5 µM) combined with estra-
diol (0.1 and 0.5 µM) (Fig. 5).
Fig. 3  Bar charts showing the 
effect of rilpivirine and estradiol 
either alone or in combina-
tion on the release of leptin by 
human adipocytes in culture for 
10 days.Values are means ± SD; 
* p < 0.05 compared to 
untreated control cells; n = 6
Fig. 4  Bar charts showing the 
effect of rilpivirine and estradiol 
either alone or in combination 
on the release of adiponectin 
from human adipocytes in 
culture for 10 days. Data are 
means ± SD = 6; *p < 0.05 for 
all concentrations of the drugs 
compared to control, except for 
1 µM rilpivirine
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Figure 6 shows the effect of rilpivirine and estradiol either 
alone or in combination on the release of IL-8 from human 
adipocytes in culture for 10 days. The data reveal a signifi-
cant (p < 0.05) release in IL-8 for only 10 µM rilpivirine 
compared to untreated control. The other drug treatments 
only evoked small increases (but not significant, p > 0.05) 
in IL-8 compared to untreated control cells.
Measurement of free glycerol and adipocytokines 
from human adipocytes treated with various 
concentrations of rilpivirine and estradiol 
either alone or in combination but in the continuous 
presence of 200 µM β‑naphthoflavone (BNF)
In this series of experiments the human adipocytes were 
pretreated with BNF followed by treatment with either rilpi-
virine or estradiol alone or during their combination employ-
ing different doses. The rationale was to ascertain whether 
Fig. 5  Bar charts showing the 
effect of rilpivirine and estradiol 
either alone or in combina-
tion on the release of resistin 
from human adipocytes in 
culture for 10 days. Values are 
means ± SD; n = 6; *p < 0.05 for 
all drug treatments compared to 
untreated control except for 1 
and 5 µM rilpivirine alone and 
when rilpivirine (1 and 5 µM) 
was combined with estradiol 
(0.1 and 0.5 µM)
Fig. 6  Bar charts showing the 
effect of rilpivirine and estradiol 
either alone or in combination 
on the release of interleukin-8 
from human adipocytes in 
culture for 10 days. Data as 
means ± SD; n = 6; *p < 0.05 for 
10 µM rilpivirine compared to 
untreated control
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BNF might exert an attenuating or potentiating effect on 
lipolysis and the release of adipocytokines from human 
adipocytes.
Figure 7 shows the effect of different doses of rilpivirine 
and estradiol either alone or following combination in the 
presence of 200 µM of BNF on the release of free glyc-
erol from human adipocytes in culture over 10 days with 
the drugs. The results show that all drug treatments can 
evoke significant (p < 0.05) dose-dependent release in free 
glycerol compared to untreated control. These effects were 
much larger compared the results obtained in the absence of 
BNF (see Fig. 2 for comparison).
Figure 8 shows the effect of different concentrations of 
rilpivirine or estradiol either alone or in combination and in 
the presence of 200 µM of BNF on the release of leptin by 
human adipocytes in culture for 10 days with the drugs. The 
results show that only 10 µM rilpivirine alone and 10 µM 
rilpivirine in combination with 0.1 µM estradiol with BNF 
Fig. 7  Bar charts showing the 
effect of different concentrations 
of rilpivirine and estradiol either 
alone or following combina-
tion in the presence of 200 µM 
of BNF on the release of free 
glycerol from human adipocytes 
in culture over 10 days with the 
drugs. In this and subsequent 
figures human pre-adipocytes 
were differentiated in culture 
in the presence of the indicated 
concentrations of drugs. Values 
are means ± SD; n = 6; *p < 0.05 
for all drug treatments com-
pared to untreated control cells
Fig. 8  Bar charts showing the 
effect of different concentrations 
of rilpivirine or estradiol either 
alone or in combination and 
in the presence of 200 µM of 
BNF on the release of leptin by 
human adipocytes in culture for 
10 days with the drugs. Values 
are means ± SD; n = 6; *p < 0.05
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can evoke significant (p < 0.05) decreases in leptin compared 
to untreated control.
Figure 9 shows the effect of different concentrations of 
rilpivirine and estradiol either alone or in combination and 
in the presence of 200 µM of BNF on the release of adi-
ponectin by human adipocytes in culture for 10 days with 
the drugs. The results show significant (p < 0.05) decreases 
in adiponectin release for all drug treatments compared to 
untreated control. The decrease in adiponectin level was 
dose dependent, but much more marked in the presence of 
BNF.
Figure 10 shows the effect of rilpivirine and estradiol 
either alone or in combination and in the presence of 200 µM 
of BNF on the release of resistin from human adipocytes in 
culture for all drugs. The results show a significant (p < 0.05) 
release in resistin for 10 µM rilpivirine, all concentrations of 
estradiol and rilpivirine (10 µM) in combination with estra-
diol (0.1 µM) and BNF compared to untreated control.
Figure 11 shows the effect rilpivirine and estradiol either 
alone or in combination and in the presence of 200 µM 
of BNF on the release of IL-8 from human adipocytes in 
culture for 10 days with all the drugs. The results show a 
Fig. 9  Bar graph showing the 
effect of different concentrations 
of rilpivirine and estradiol either 
alone or in combination and in 
the presence of 200 µM of BNF 
on the release of adiponectin by 
human adipocytes in culture for 
10 days with the drugs. Values 
are means ± SD; n = 6; *p < 0.05 
for all drug treatments com-
pared to untreated control
Fig. 10  Bar graph showing the 
effect of rilpivirine and estradiol 
either alone or in combination 
and in the presence of 200 µM 
of BNF on the release of resistin 
from human adipocytes in 
culture for all the drugs. Values 
are means ± SD; n = 6; *p < 0.05 
for drug treated cells untreated 
control cells
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significant (p < 0.05) decrease in the release of IL-8 for 1 
and 5 µM rilpivirine, 0.01 and 0.05 µM estradiol compared 
to untreated cells.
Discussion
The results of this study have demonstrated marked morpho-
logical changes in the adipocytes in culture over time. The 
cells were observed daily as they were proceeding through 
the foregoing stages of differentiation. Microphotographs 
were taken on day 0, day 5 and day 10 for comparison. The 
results show that the shape of the cells changed from the 
spindle- shaped fibroblast to the nearly spherical form of a 
mature adipose cell. There was an increasing accumulation 
of lipid, first as small inclusions concentrated towards one 
pole of the cell and then finally as large lipid masses in the 
central region of the cell.
Viability of the cells were assessed on 0, 5 and 10th day 
of the adipocyte maturation process by employing lactate 
dehydrogenase as a marker to monitor cell death. Increas-
ing concentrations of rilpivirine (1 µM, 5 µM and 10 µM) 
and estradiol (0.01 µM, 0.05 µM and 0.1 µM) were tried 
individually and in combination. The results clearly show 
that neither rilpivirine nor estradiol either alone or in com-
bination with or without BNF had any deleterious effects 
on the viability of adipocytes compared to untreated cells. 
There was no significant release of LDH in stimulated or 
treated cells as compare to untreated cells. The viability 
of cells at all stages of adipogenesis, as measured by the 
lactate dehydrogenase assay, did not show any significant 
difference as compared to the control. Therefore, all these 
concentrations were determined as optimal for future 
experimental work. These results are in agreement with 
a previous study [26].
Data from several previous studies have revealed that 
anti-retroviral and estrogen therapy induces lipid alterations 
by activating lipolysis and thereby, enhancing the levels of 
free fatty acid and free glycerol in adipocyte cell cultures 
[27–29].
The results of this study show an increasing trend in the 
lipolysis process in human adipocytes. The release of glyc-
erol was dose-dependent with both rilpivirine and estra-
diol. Concomitant treatment of two drugs at all doses did 
not show any attenuation or potentiating effect on glycerol 
release, but only a small additive effect compared to the 
effect of either rilpivirine or estradiol alone. The observed 
results could be attributed to impaired GLUT4 transloca-
tion and are in keeping with another study that assessed 
the effect of nelfinavir on glucose uptake and lipolysis in 
differentiated 3T3-L1 adipocytes [30]. An 18-h exposure 
to nelfinavir resulted in an impaired insulin-stimulated glu-
cose uptake and activation of basal lipolysis with as low as 
5 µmol/l nelfinavir [30]. Another study conducted in vivo 
showed that exposure to high concentrations of estradiol led 
to region-and pathway-dependent modulation of subcutane-
ous adipose tissue lipolysis in pre-menopausal women [31].
Leptin has been reported to be related to adiposity and it 
increases in proportion to decreasing adipose tissue stores. 
It is of much interest in anti-retroviral and estrogen-based 
Fig. 11  Bar charts showing the 
effect rilpivirine and estradiol 
either alone or in combina-
tion and in the presence of 
200 µM of BNF on the release 
of interleukin-8 from human 
adipocytes in culture for 10 days 
with all the drugs. Values are 
mean ± SD; n = 6; *p < 0.05 for 
1 µM and 5 rilpivirine, 0.01 and 
0.05 µM estradiol compared to 
untreated cells
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therapies where abnormalities of body fat distribution are 
characteristic features. A number of in vitro studies have 
demonstrated a reduction in leptin secretion when human 
adipocytes were treated with ARVs [32, 33]. In this study, 
no significant release in leptin level were observed when 
adipocytes were treated with either all concentrations of 
estradiol or low doses of rilpivirine compared to a higher 
dose of 10 µM which elicited a significant decrease in leptin 
secretion compared to untreated cells. Similar results were 
obtained with the highest dose of each drug when they were 
combined. Previous in vivo and in vitro studies reported that 
estrogens can elevate the level of leptin [34, 35].However, 
some reports have indicated either a nil or a reverse relation-
ship between estrogens and leptin release [36, 37].
Adiponectin, an insulin-sensitizing adipokine, is induced 
during adipocyte differentiation [38]. Reduced levels of adi-
ponectin have been reported by various studies in adipocytes 
treated with very high doses of ARV drugs. In the present 
study, except for at a low concentration (1 µM) of rilpivirine 
alone, all the other drug treatments elicited significant effects 
on the release of adiponectin levels from human adipocytes. 
Combining rilpivirine with estradiol produced a much larger 
decrease in the release of adiponectin compared to their 
individual concentrations alone. Adiponectin is known to 
enhance insulin-mediated glucose uptake in peripheral tis-
sues (i.e., skeletal muscle) and in sensitizing liver to insulin-
dependent suppression of glucose output [39]. This reduc-
tion may be considered as a major contributor to insulin 
resistance (IR). In this study, reduced levels of adiponectin 
were observed when cells were treated with increasing doses 
of 17β-estradiol. The present results are in agreement with 
a recent study that reported dramatically suppressed levels 
of adiponectin concentration when pre-adipocytes were 
exposed to increasing levels of 17β-estradiol [40].
Originally, resistin was thought to be a link between dia-
betes and obesity. A single nucleotide polymorphism in the 
resistin gene has been associated with elevated lipids, IR and 
body composition changes among HIV-infected individuals 
on anti-retroviral therapies [41]. In another study, greater 
plasma resistin levels were observed in HIV patients com-
pared with uninfected controls [42]. However, other workers 
have found no association between serum resistin and fat 
redistribution, and metabolic profile in HIV-infected patients 
[43, 44]. The physiological role of resistin, therefore, is not 
fully understood and needs further studies. It is proposed 
to be an important peptide bringing about IR and obesity, 
although it is still debatable [45].In the present study, the 
levels of resistin were comparable to that of control and there 
was no significant difference for pre-adipocytes treated indi-
vidually with rilpivirine at low doses. Only a slight increase 
in the resistin level was observed at 10 µM, indicating that 
rilpivirine may contribute to the fat re-distribution but 
only at high dosage. A positive correlation in estrogens 
and resistin levels has been demonstrated and resistin con-
centrations were found to be conspicuously elevated by 
17β-estradiol [40, 46]. The present study showed enhanced 
levels of resistin in adipose cells treated with different con-
centrations of 17β-estradiol as compared to control. Combi-
nation of rilpivirine and estradiol did not show any increase 
in resistin level for the lowest and median doses used in the 
study. However, an increase in the resistin concentrations 
was observed at the highest dosage of combination treatment 
(1 µM rilpivirine combined with 0.1 µM estradiol).
Increased serum IL-8 levels have been previously 
reported in HIV patients with impaired glucose tolerance 
[47], and this is consistent with findings in T2DM [48], 
obesity and non-alcoholic fatty liver disease [49]. Chronic 
inflammatory state in HIV-infection may be associated with 
elevated fasting serum level of IL-8. Higher serum IL-8 may 
also reflect increased production and release from the larger 
adipose depots and may have an influence on lipid metab-
olism along with its effect on insulin resistance. Elevated 
levels of IL-8 have been observed in human subcutaneous 
and visceral adipose tissue obtained from HIV-infected peo-
ple with fat redistribution and insulin resistance [50]. In the 
present study, IL-8 levels increased with an increase in the 
concentrations of rilpivirine. High concentrations of IL-8 
were observed when the cells were treated with 10 µM of 
rilpivirine indicating its role in fat re-distribution. The pre-
sent findings are in agreement with another study [26],which 
reported that rilpivirine did not have any effect on the release 
of IL-8 at concentrations up to 4 µM, but instead, it produced 
a marked and significant elevation only at 10 µM. Compared 
to rilpivirine, estradiol evoked a dose-dependent increase in 
the release of IL-8 from adipose cells. Enhanced levels of 
IL-8 were observed when the pre-adipocytes were treated 
with increasing concentrations of estradiol. Moreover, 
increasing release in the level of IL-8 was observed when 
adipocytes were treated with a combination of rilpivirine 
and estradiol suggesting a major contribution of estradiol in 
eliciting the release of IL-8.
In the second series of experiments human adipocytes 
were pretreated with BNF in the absence and presence of 
either rilpivirine, estradiol or when the two drugs were com-
bined for a period of 10 days. The results reveal elevated 
glycerol level with BNF alone. When BNF was combined 
with either rilpivirine, estradiol or both drugs, there were 
enhanced release of glycerol in a dose-dependent manner. 
BNF seems to be potentiating the effect of either rilpivirine 
or estradiol on glycerol release (enhanced lipolysis) from 
human adipocytes. In contrast, BNF had no significant 
effect on the release of leptin from human adipocytes when 
combined with either rilpivirine, estradiol or with both. In 
this series, BNF also enhanced the decrease in adiponec-
tin release from human adipocytes in the presence of either 
rilpivirine, estradiol or when the two drugs were combined 
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compared to the results obtained in the absence of BNF. 
In contrast, in the presence of BNF, individual treatment 
of adipose cells with either rilpivirine or estradiol alone or 
combined did not seem to have any significant effect on the 
resistin and IL-8 releases for all the doses used in the study 
compared to the results obtained in the absence of BNF. In 
fact BNF seemed to induce a reduction in the levels of resis-
tin and IL-8 as compared to levels in the absence of BNF.
Conclusion
From the results of this study, it is possible to conclude that 
a combination of rilpivirine and 17β-estradiol is completely 
non-toxic to pre-adipocytes at most concentrations tested. 
During the 10-day exposure to the drugs, only estradiol 
produced a modest cytotoxic effect at the highest concen-
trations. No profound deleterious effect was on adipose 
tissue development or the endocrine function of adipose 
tissue (adipokine and cytokine release) in treated 3T3-L1 
human pre-adipocytes. However, caution should be main-
tained considering that other transcriptional factors play a 
crucial role in overall alterations of lipid metabolism. BNF 
does not seem to significantly interact with rilpivirine and 
17β-estradiol except for the release of adiponectin. Moreo-
ver, in order to establish and elucidate a significant effect 
of these drugs on the adipogenic process, studies at gene 
expression levels and involving the markers of oxidative 
stress are required.
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